Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on June 27, 2018. The report discloses a material event regarding the company's clinical development program for its investigational drug, PCM-075.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements.
Material Changes
The primary material change reported is the announcement of preliminary clinical data from the first dosing cohort of an ongoing Phase 1b/2 trial. The data indicates a treatment effect for PCM-075 in combination with low-dose cytarabine (LDAC) or decitabine in patients with relapsed or refractory Acute Myeloid Leukemia (AML). The effect was measured by decreases in leukemic cells in both peripheral blood and bone marrow.
Guidance, Outlook, and Risks
Management commentary is limited to the press release details regarding the positive preliminary data. The filing does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the inherent nature of clinical trials. No unusual items were reported.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical data on the treatment effect.
- Confirm the specific patient population size and response rates in the first dosing cohort.
- Review the company's cash runway and funding status in recent 10-Q or 10-K filings, as this 8-K contains no financial data.
- Monitor subsequent regulatory filings for updates on the Phase 1b/2 trial progression.